Check out your Company Bowl for anonymous work chats.
Big news, as Dendreon signs its first CMS (CMO/CDMO) partnership!
SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, has established and invested in its new contract manufacturing and services division to bring late-stage clinical assets through to commercialization. Leveraging its extensive manufacturing, process development and logistics expertise, Dendreon now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs. “We are enabling the future of immunotherapy and supporting an unmet need in the market with immediate access to capacity and expertise” Tweet this “Innovative cell therapies have the potential to change how we treat serious diseases, but there is currently insufficient capacity to meet anticipated industry demand,” said Jason O’Neill, Chief Executive Officer of Dendreon. “With more than a decade of proven expertise in cell therapy manufacturing and an established supply chain and logistics infrastructure, we have invested in an offering that fills an immediate market need i
